Effects of Curcumin on Improving Mild Cognitive Impairment in Adults and Elderly Subjects with Metabolic Syndrome: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210304001

Enrollment

150

Registered

2021-03-04

Start date

2021-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome patients with mild cognitive impairment metabolic syndrome mild cognitive impairment cognitive dysfunction mild neurocognitive disorder

Interventions

Taking curcumin capsule orally 1,500 gm per day for 6 months,Taking placebo capsule orally with a similar amount to an intervention arm for 6 months

Experimental Drug,Placebo Comparator Drug

Curcumin,Placebo

Eligibility

Sex/Gender

All

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: Metabolic syndrome patients with mild cognitive impairment Age 45-75 years old

Exclusion criteria

Exclusion criteria: 1. Prior diagnosis of dementia or positive screening for dementia 2. Having depression 3. Recent infected or anti-biotic use within 4 weeks 4. Recent surgery less than 3 months 5. Chronic kidney disease stage 4 and 5 6. Having cancer with active treatment or autoimmune disease 7. Allergy to curcumin 8. Abnormal liver function test

Design outcomes

Primary

Measure	Time frame
cognitive performance at 6 months MONTREAL COGNITIVE ASSESSMENT (MoCA) test	—

Secondary

Measure	Time frame
Biomarkers at 6 months Changes in biomarkers, inflammatory proteins, and oxidative stress indicator	—

Countries

Thailand

Contacts

Public ContactKanokporn Pinyopornpanish

Faculty of Medicine, Chiang Mai University

KNP_02@HOTMAIL.COM6653935462

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026